Statins
Verified · Oct 2026Prototype: atorvastatin
Statins are a class of medications used for hyperlipidemia.
Medical view → mechanisms, drug comparisons and Step 1 pharmacology
HMG-CoA reductase inhibitors. Recognizable by the generic stem -vastatin.
How it works in the body
The system involved, what goes wrong, and how the drug and body interact.
01 Cholesterol, LDL, and how arteries clog
Cholesterol is essential — it builds cell membranes and hormones — but it travels through blood packaged in particles. LDL ("bad") cholesterol delivers cholesterol to tissues; HDL ("good") carries it back to the liver. When there is too much LDL, it seeps into artery walls, is oxidized, and is swallowed by immune cells to form fatty plaque — the disease called atherosclerosis.
Plaque narrows arteries and, more dangerously, can rupture — triggering a clot that causes a heart attack or stroke. Lowering LDL both slows plaque growth and makes existing plaque more stable (less likely to rupture). That is the whole therapeutic goal.
02 The liver’s cholesterol assembly line
Cholesterol comes both from the diet and from the body’s own production — and the liver is the main factory. The production line runs from a building block (HMG-CoA) through a series of steps to cholesterol, and the rate-limiting step — the slowest, controlling valve of the whole line — is an enzyme called HMG-CoA reductase.
Whoever controls that enzyme controls how much cholesterol the liver makes. That is exactly where statins act.
03 How statins intervene
A statin competitively blocks HMG-CoA reductase, so the liver makes less cholesterol internally. Sensing it now has too little, the liver cell responds by building more LDL receptors on its surface and pulling LDL out of the bloodstream to compensate.
That second step is the key: it isn’t just that the liver makes less — it actively clears circulating LDL, which is what lowers the number on the lab report. Because hepatic cholesterol synthesis peaks in the early-morning hours, short-acting statins (such as simvastatin) are dosed in the evening. Labels differ, though: lovastatin is taken with meals (starting with the evening meal), while the pravastatin label allows any time of day.
04 How the body reacts — the muscle, glucose, and liver effects
The class’s hallmark side effect is muscle symptoms, ranging from mild aches to — rarely — rhabdomyolysis, where muscle breaks down and releases myoglobin that can injure the kidneys. One proposed explanation is that statins deplete coenzyme Q10, disrupting energy production in muscle-cell mitochondria. Risk climbs with high doses, interacting drugs (that raise statin levels), advanced age, and kidney impairment.
Statins also modestly raise blood glucose (a small increase in new-onset diabetes) and can bump liver enzymes. These are monitored but rarely outweigh the large cardiovascular benefit.
05 Beyond statins — the non-statin add-ons
Statins are first-line, but when LDL is still too high (or statins aren’t tolerated) several non-statin drugs are added on. Ezetimibe (Zetia) blocks the intestinal cholesterol transporter NPC1L1, cutting absorption of dietary/biliary cholesterol — a modest ~13–20% LDL drop that pairs well with a statin. The PCSK9 inhibitors — the injectable monoclonal antibodies alirocumab and evolocumab (the "-mab" drugs), plus the siRNA inclisiran — stop the liver from destroying its own LDL receptors, so more receptors clear more LDL, dropping it by up to ~60% for high-risk patients.
Fibrates (fenofibrate, gemfibrozil) are a different tool: they activate PPAR-α to mainly lower triglycerides and raise HDL, used for very high triglycerides rather than LDL. The key nursing caution is overlap toxicity — fibrates (especially gemfibrozil) added to a statin raise the risk of myopathy/rhabdomyolysis, so the combination is used carefully. (Bile-acid sequestrants and nicotinic acid (niacin) are other lipid-lowering classes; sequestrants are the preferred lipid drug in pregnancy.)
Drug names
Indications
- Hyperlipidemia (elevated LDL cholesterol)
- Primary & secondary prevention of atherosclerotic cardiovascular disease (ASCVD)
Mechanism of action
Competitively inhibit HMG-CoA reductase, the rate-limiting enzyme of hepatic cholesterol synthesis — upregulating LDL receptors and lowering circulating LDL; also stabilize atherosclerotic plaque.
Therapeutic effects — what you'll see working
Statins are judged not by how a patient feels — the benefit is silent — but by the LDL number and long-term reduction in heart attacks and strokes. Effects on the lab panel appear within weeks; the cardiovascular payoff accrues over years.
- ↓ LDL cholesterol
- Upregulated liver LDL receptors clear LDL from the blood, typically lowering it 30–50% depending on the statin and dose. This is the primary, measurable effect.
- Plaque stabilization
- Beyond the number, statins make existing plaque less inflamed and less likely to rupture — which is why they cut heart-attack and stroke risk even when LDL is only modestly high.
Adverse effects
The side effects cluster in three places: muscle (aches up to, rarely, rhabdomyolysis), glucose (a small rise and more new-onset diabetes), and the liver (usually transient enzyme rises).
Interactions
Contraindications
Because the liver both clears statins and is where they act, liver disease is the central concern; interactions matter because they raise statin blood levels into the myopathy range.
Labs & levels
Nursing considerations
The RN-specific layer — each action paired with the reason it matters.
Common questions
What are Statins used for?
How do Statins work?
What are the serious side effects of Statins?
What labs should be monitored with Statins?
Conditions treated
A high-intensity statin (atorvastatin 80 mg or rosuvastatin 20–40 mg) for all ACS patients (Class 1, Level A): plaque stabilization now, LDL lowering for life. LDL-C still ≥ 70 mg/dL on a maximally tolerated statin means adding a nonstatin (ezetimibe, evolocumab, alirocumab, inclisiran, or bempedoic acid).
Statins "remain the first-line therapy for dyslipidemia" in chronic coronary disease (StatPearls). Recommended for all CAD patients if tolerated: high-intensity therapy (atorvastatin 40–80 mg or rosuvastatin 20–40 mg) targeting ≥ 50% LDL-C reduction and an LDL < 70 mg/dL. If the goal isn’t reached, ezetimibe is added first, then a PCSK9 inhibitor.
Aimed at the hyperlipidemia, and worth teaching with the caveat attached. A meta-analysis showed limited effectiveness of statins in reducing dyslipidaemia in this specific population — unsurprising, since the defect is impaired clearance rather than pure overproduction. But statins "seem to be very well tolerated in patients with nephrotic syndrome and have a low adverse effect profile," and the mechanism review concludes they should be first-line treatment for prolonged hyperlipidaemia here. The justification is the cardiovascular risk: MI relative risk 5.5, coronary death 2.8.
Lipids in metabolic syndrome. NHLBI: "Medicines such as statins and niacin can help lower triglyceride and “bad” LDL cholesterol levels." "Some statins can raise the risk of type 2 diabetes in people who have metabolic syndrome."
For every PAD patient regardless of LDL — high-intensity statin therapy aiming for a ≥ 50% LDL-C reduction (ACC/AHA 2024, Class 1), with ezetimibe or a PCSK9 inhibitor added if LDL-C stays ≥ 70 mg/dL on the maximal tolerated dose. The disorder-specific payoff is the limb as much as the heart: statins cut major adverse limb events by about 30%, amputation by 35%, and all-cause death by 39% in meta-analysis — yet they remain underprescribed in PAD. Teach that leg muscle aches in a claudicant are usually the disease, not the drug; statins have proven safe in large PAD cohorts.
High-intensity statin (atorvastatin 80 mg or rosuvastatin 20 mg daily) after ischemic stroke or TIA in patients under 75 with clinical atherosclerotic disease — large-artery atherosclerosis is the dominant stroke substrate, and TIA management pairs high-dose statin therapy with BP and glycemic control.
"Hyperlipidemia control with HMG-CoA reductase inhibitors also improves patient survival in kidney transplant recipients."
See also
Slow heart rate & lower BP by blocking β-adrenergic receptors. Watch for bradycardia.
Lower BP by blocking angiotensin conversion. Classic dry cough & angioedema risk.
Injectable antibodies that protect the liver’s LDL receptors, cutting LDL cholesterol by about half and lowering cardiovascular events. Given subcutaneously every 2–4 weeks.
PPAR-α agonists that mainly lower triglycerides — used with diet for severe hypertriglyceridemia — with muscle, gallbladder, liver and kidney risks, highest for gemfibrozil combined with a statin.
Non-absorbed resins that trap bile acids in the gut, forcing the liver to use cholesterol and pull LDL from the blood. Constipation, drug binding and rising triglycerides are the issues to manage.
Six non-statin drugs with six targets: ezetimibe (intestinal cholesterol absorption), bempedoic acid (liver cholesterol synthesis), inclisiran (PCSK9 mRNA), niacin and icosapent ethyl (triglyceride-rich lipoproteins) and lomitapide (MTP, for homozygous FH only).
Sources
- Atorvastatin — adverse effects, myopathy, contraindications — StatPearls (NCBI)
- Ezetimibe — NPC1L1 cholesterol-absorption inhibition, ~13–20% LDL reduction (non-statin note) — StatPearls (NCBI)
- PCSK9 Inhibitors — alirocumab/evolocumab/inclisiran, up to ~60% LDL reduction (non-statin note) — StatPearls (NCBI)
- Fibric Acid Antilipemic Agents — PPAR-α, triglyceride lowering, statin-combination myopathy risk — StatPearls (NCBI)
- Lipitor (atorvastatin) — current FDA label: contraindications, myopathy, hepatic testing, pregnancy — FDA / DailyMed
- Crestor (rosuvastatin) — FDA label — FDA / DailyMed
- Zocor (simvastatin) — FDA label: evening dosing, CYP3A4 and gemfibrozil contraindications, grapefruit — FDA / DailyMed
- Zetia (ezetimibe) — FDA label — FDA / DailyMed
- Statin Medications — mechanism, dosing time, monitoring, interactions — StatPearls (NCBI)
- Biochemistry, Cholesterol — synthesis and the rate-limiting HMG-CoA reductase step — StatPearls (NCBI)
- Atherosclerosis — LDL, foam cells, plaque rupture and thrombosis — StatPearls (NCBI)
- Rhabdomyolysis — myoglobin, kidney injury, CK thresholds — StatPearls (NCBI)
- Liver Function Tests — typical ALT/AST reference ranges — StatPearls (NCBI)
- Simvastatin — evening dosing, grapefruit, myopathy — StatPearls (NCBI)
- The use of stems in the selection of International Nonproprietary Names (-vastatin, -mab) — World Health Organization
- Biochemistry, LDL Cholesterol — LDL receptors set plasma LDL — StatPearls (NCBI)
- Pravastatin sodium tablets (Aurobindo) — FDA label: OATP1B1 interactions, any-time dosing, myopathy and hepatic warnings — FDA / DailyMed
- Lovastatin tablets (Lupin) — FDA label: contraindications, CYP3A4 interactions, take with meals — FDA / DailyMed
- Pravastatin — mechanism, LDL-receptor upregulation — StatPearls (NCBI)
Reviewed by Hae Suk Lee, RN
Educational summary for nursing students. Always verify against current prescribing information and your institution's protocols before administering. Not medical advice.